FGF2

(redirected from FGFB)
Also found in: Acronyms.

FGF2

A gene on chromosome 4q26 that encodes fibroblast growth factor 2 of the FGF family, which bind heparin and have a broad range of cellular activities, including cell survival, division, differentiation and migration. FGF2 plays a key role in various processes, including limb and nervous system development, wound healing and tumour growth, as well as angiogenesis. It is expressed in normal ovarian tissue and in hepatocellular carcinoma, but not in normal liver cells. FGF2 interacts with FGF receptors FGFR1, -2, -3 and -4.
Mentioned in ?
References in periodicals archive ?
FGFb was negatively correlated with INR (P = 0.04) and positively associated with albumin levels (P = 0.026).
[11] have shown upregulation in levels of CXCL-10, IL-12p40, IFN-[alpha]2, LTA, TRAIL, and IL-18 and downregulation of IL-17, IL-1[beta], FGFb, PDGF-BB, IFN-[gamma], and IL-4 in patients persistently infected with HCV as compared to healthy individuals.
After antiviral therapy, our results demonstrated significant changes in serum levels of CCL-2, CCL-3, CCL-4, CXCL-8, CXCL-10, IL-4, IL-10, TGF-[beta], IFN-[gamma], IL-1[beta], IL-15, FGFb, and PAI-1, in association with viral clearance.
ALT: Alanine aminotransferase APRI: Platelet ratio index AST: Aspartate aminotransferase CCL: Chemokine C-C ligand CSF: Colony stimulation factor CXCL: Chemokine X-C ligand DAA: Direct-acting antiviral agents DCV: Daclatasvir FGFb: Basic fibroblast growth factor FIB-4: Fibrosis-4 index GGT: Gamma-glutamyl transferase HCV: Hepatitis C virus IFN: Interferon IL: Interleukin INR: International normalized ratio PAI-1: Plasminogen activator inhibitor type 1 PDGF-BB: Platelet-derived growth factor BB PT: Prothrombin time RBV: Ribavirin SMV: Simeprevir SOF: Sofosbuvir suPAR: Soluble urokinase-type plasminogen activator receptor SVR: Sustained virological response TGF-[beta]: Transforming growth factor beta TNF: Tumor necrosis factor VEGF: Vascular endothelial growth factor.
(Only FGFb 10 ng/ml had significantly higher mineralization compared to OIM alone marked by the symbols **.) This was not evident in higher concentrations of FGFb (Figure 4).
Significant differentiation was shown to occur by adding FGFb to the OIM; however, this differentiation was not shown to be significantly affected by BMP2, NELL1, and a combination of BMP2 and NELL1.
The OIM with FGFb 10 ng/ml showed significantly higher quantification than OIM alone.
As a result of this, the precision regarding individual growth factors in different concentrations may be compromised and may not be included in the context of whether FGFb, BMP2, and NELL1 will boost commitment to osteogenic differentiation and thereby osteogenic lineage or not.